生物化学与分子生物学博士专业
Doctoral Program in Biochemistry and Molecular Biology
导师介绍 Supervisor Profiles
李冠武 Guanwu Li
邮箱及联系电话：gwli@stu.edu.cn, 86-13612396599
Email & Contact Number：gwli@stu.edu.cn, 86-13612396599
研究方向 ：细胞自噬与肿瘤
Research Field：Autophagy and Tumor
导师简介 Biography：
李冠武，男， 1999 年毕业于中国科技大学生命科学学院，获生化与分子生物学 专业理学博士学位。汕头大学医学院肿瘤分子生物开放实验室负责人， 生化与分 子生物学专业教授，具有硕士生导师、博士后合作导师资格。其课题组对于白藜 芦醇诱导肿瘤细胞凋亡、自噬有多年的研究基础， 主要研究方向为细胞自噬和凋 亡的相互联系及转换机制。已有 8 名研究生完成白藜芦醇对食管癌细胞、白血病 细胞和肺腺癌细胞自噬的研究。目前主要围绕肿瘤药物诱导细胞自噬及相关机制 的研究，研究发现细胞自噬的作用并不仅仅限于传统意义的细胞保护作用，细胞 自噬也是细胞死亡的机制之一，甚至可能是某些细胞凋亡的必经之路。作为项目 负责人，先后主持各种科研项目，包括国家自然科学基金面上项目、教育部霍英 东基金、广东省自然科学基金面上项目以及广东省科学技术厅项目等。作为导师， 指导硕士研究生累计 30 余名，在读研究生 5 名；指导本科大学生从事创新科学 研究 15 人（获得大创项目三项，其中省级两项目、国家级一项）； 近五年来，在 J Cellular Physiology 、Cancer Letter、Biochemical Pharmacology 等国际学术期刊 上发表研究论文。
最近他的课题组研究发现 LC3 通过线粒体自噬及 Pink1/Parkin 通路，参与细胞自 噬和凋亡之间转换的调控。
Guanwu Li, graduated from The School of Life Sciences, University of Science and Technology of China in 1999 with a doctorate degree in Biochemistry and Molecular Biology. Now he is the Director of the Open Laboratory of Molecular Oncology, Shantou University Medical College, Professor in Biochemistry and Molecular Biology, master supervisor and postdoctoral co-supervisor. The research group has many years of research foundation on resveratrol-induced apoptosis and autophagy in tumor, and the interaction and transformation mechanism of autophagy and apoptosis.
At present, the research mainly focuses on the tumor drug-induced autophagy and related mechanisms. It has been found that autophagy is not only limited to the traditional protective effect of cells, but also one of the mechanisms of cell death, and may even be the dependent way of apoptosis in some cells.
Recently, his research group found that LC3 is involved in the regulation of the transition between autophagy and apoptosis through mitochondrial autophagy and Pink1/Parkin pathway.
代表性研究论文(共同第一作者或通讯作者)： Publication list：
[1] Li G, He S, Chang L, Lu H, Zhang H, Zhang H, Chiu J. GADD45α and annexin A1 are involved in the apoptosis of HL-60 induced by resveratrol. Phytomedicine. 2011 Jun 15;18(8-9):704-9
[2] Li G, Lee LS#, Li M, Tsao SW, Chiu JF. Molecular Changes during Arsenic-Induced Cell Transformation. J Cell Physiol. 2011 Dec;226(12):3225-32.
[3] Jiao RQ, Li G, Chiu JF. Comparative proteomic analysis of differentiation of mouse F9 embryonic carcinoma cells induced by retinoic acid. J Cell Biochem. 2012 Jun;113(6):1811-9.
[4] Tang Q, Li G#, Wei X, Zhang J, Chiu JF, Hasenmayer D, Zhang D, Zhang H. Resveratrol-induced apoptosis is enhanced by inhibition of autophagy in esophageal squamous cell carcinoma. Cancer Lett. 2013 Aug 19;336(2):325-37.
[5] Jun Zhang, JenFu Chiu, Hongwei Zhang, Tingting Qi, Qishan Tang, Ke Ma, Hong Lu, Guanwu Li*, Autophagic cell death induced by resveratrol depends on the Ca2+/AMPK/mTOR pathway in A549 cells. Biochemical Pharmacology. 2013 July 86( 2), 317–328.
[6] Jun Zhang, Ke Ma, Tingting Qi, Xiaoning Wei, Qing Zhang, Guanwu Li* and Jen-Fu Chiu*. P62 regulates resveratrol-mediated Fas/Cav-1 complex formation and transition from autophagy to apoptosis. Oncotarget. 2015 Jan 20;6(2):789-801
[7] Yingying Fan, Jen-Fu Chiu, Jing Liu, Yan Deng, Cheng Xu, Jun Zhang, and Guanwu Li. Resveratrol induces autophagy-dependent apoptosis in HL-60 cells. BMC Cancer, Volume 18, Issue 1, 22 May 2018,581
[8] Ningyu Huang, Xiaojuan Pei, Wenbo Lin, Jen-Fu Chiu, Tao Tao, and Guanwu Li. DNA methylation of a non-CpG island promoter represses NQO1 expression in rat arsenic-transformed lung epithelial cells. Acta Biochim Biophys Sin，2018, 50(8), 733–739
[9] Jiahua Zheng, ShaochaiWei,TingtingXiao, Guanwu Li*. LC3B/p62-mediated mitophagy protects A549 cells from resveratrol-induced apoptosis. Life Sciences,Volume 271, 15 April 2021, 119139
东庚 Geng Dong
邮箱及联系电话:gdong@stu.edu.cn
Email & Contact Number：gdong@stu.edu.cn
研究方向: 计算生物化学
Research Field: Computational Biochemistry
导师简介 Biography：
汕头大学医学院特聘教授，博导。2018 年 7 月获瑞典隆德大学（Lund University） 理论化学专业博士学位。2018 年 9 月入职汕头大学医学院，研究领域是计算生 物化学。研究方向是通过理论计算模拟等手段/信息技术平台研究：1）肿瘤中生 物酶酶促反应机理，揭示其分子作用机制及其结构-功能关系；2）与肿瘤相关的 蛋白-蛋白或药物-蛋白之间相互作用， 以及分子对接后对蛋白结构的影响，为药 物的临床转化研究提供理论依据。作为研究生导师，指导硕士研究生 5 人，博 士研究生 3 人。在《J. Am. Chem. Soc.》 、《Chem. Sci.》和《ACS Catal.》等国 际主流学术杂志发表研究论文 27 篇。参与著书一部。个人网页：
https://www.x-mol.com/groups/Dong
Prof. Dr. Geng Dong received his PhD in 2018 working with Prof. Ulf Ryde. Then, he joined Shantou University Medical College for computational biochemistry as group leader. Dong has published 27 scientific articles in journals of chemistry and biochemistry. His work focuses on the reaction mechanism of enzymes, ligand binding, protein-protein interaction, as well as drug design by using theoretical methods, e.g., QM cluster calculation, QM/MM calculation, MD simulation etc.
More information can be found on https://www.x-mol.com/groups/Dong.
邹海鹰 Haiying Zou
邮箱及联系电话：zouhy@stu.edu.cn, 86-13670533016
Email & Contact Number：zouhy@stu.edu.cn, 86-13670533016
研究方向：肿瘤分子生物学
Research Field：Molecular Biology of Cancer
导师简介 Biography：
邹海鹰，副教授，博士，汕头大学医学院生物化学与分子生物学教研室学术骨干。 1997 年，华南师范大学毕业，获得生物科学学士学位。2006 年，厦门大学生命 科学院毕业，获得生物化学与分子生物学专业博士学位。2008 年，在美国纽约
州 SUNY Upstate Medical University 药理学系做博士后。主要研究方向是食管鳞 癌及其肿瘤分子生物学。迄今为止，累计发表 SCI 研究论文 20 余篇，其中通讯 作者 1 篇，第一作者 4 篇，共同第一作者 3 篇；主持广东省自然科学基金项目 2 项。
Haiying Zou, associate professor, PH.D, acts as key faculty of the Department of Biochemistry and Molecular Biology. In 1997, he graduated from South China Normal University with a bachelor's degree in biological sciences. In 2006, graduated from the School of Life Sciences, Xiamen University, with a doctorate degree in biochemistry and molecular biology. In 2008, he was a postdoctoral fellow in the Department of Pharmacology, SUNY Upstate Medical University, New York, USA. The main research direction is esophageal squamous cell carcinoma and its tumor molecular biology. So far, more than 20 research papers have been published, including 1 as corresponding author, 4 as first author, and 3 as co-first author; presided over 2 projects of the Natural Science Foundation of Guangdong Province.
代表性研究论文（ #共同第一作者， *通讯作者或共同通讯作者）： Reference:
[1] Xie W, Huang P, Wu B, Chen S, Huang Z, Wang J, Sun H, Wu J, Xie L, Cheng Y, Xie W, Xu L, Chen LQ, Li E, Zou HY*. Clinical significance of LOXL4 expression and features of LOXL4-associated protein-protein interaction network in esophageal squamous cell carcinoma Amino Acids. 2019 May;51(5):813-828. doi: 10.1007/s00726-019-02723-4.
[2] Zou HY, WenB, Li RL, Zhan XH, Jiao JW, Liao LD, Wu BL, Xie WM, Xu LY, Li EM. Lysyl oxidase-like 2 promotes esophageal squamous cell carcinoma cell migration independent of catalytic activity Int J Biochem Cell Biol. 2020; 125:105795. doi: 10.1016/j.biocel. 2020.105795.
[3] Sun H#, Zou HY#, Cai XY, Zhou HF, Li XQ, Xie WJ, Xie WM, Du ZP, Xu LY, Li EM, Wu BL. Network Analyses of the Differential Expression of Heat Shock Proteins in Glioma DNA Cell Biol. 2020;39(7):1228-1242. doi: 0.1089/dna.2020.5425.
[4] Zou HY, Lv GQ, Dai LH, Zhan XH, Jiao JW, Liao LD, Zhou TM, Li CQ, Wu BL, Xu LY, Li EM. A truncated splice variant of human lysyl oxidase-like 2 promotes migration and invasion in esophageal squamous cell carcinoma. IntJ Biochem Cell Biol. 2016.75:85-98.
[5] Lv GQ#, Zou HY#, Liao LD, Cao HH, Zeng FM, Wu BL, Xie JJ, Fang WK, Xu LY*, Li EM*. Identification of a novel lysyl oxidase-like 2 alternative splicing isoform, LOXL2 Δe13, in esophageal squamous cell carcinoma. Biochem Cell Biol. 2014;92(5):379-389.
[6] Wu BL#, Zou HY#, Lv GQ, Du ZP, Wu JY, Zhang PX, Xu LY*, Li EM*. Protein-protein Interaction Network Analyses For Elucidating the Roles of LOXL2-delta72 in Esophageal Squamous Cell Carcinoma. Asian Pac J Cancer Prev. 2014;15(5):2345-2351.
[7] Wu BL#, Lv GQ#, Zou HY#, Du ZP, Wu JY, Zhang PX, Xu LY*, Li EM*. Exploration of potential roles of a new LOXL2 splicing variant using network knowledge in esophageal squamous cell carcinoma. Scientific World Journal. 2014;2014:431792.
[8] Zou HY, Yan D, Mohi G*. Differential biological activity of disease-associated JAK2 mutants. FEBS Lett. 2011,585(7):1007-1013.
肿瘤分子学 Molecular Biology of Cancer
汕头大学医学院生物化学与分子生物学教研室是汕头大学医学院的重要基础科 室之一，也是广东省省级特色重点学科和生物学省级优势重点学科的重要组成部 分。2000 年和 2005 年分别获得生物化学与分子生物学硕士学位和博士学位授权。
目前，教研室拥有教师与教辅人员共 18 人，职称结构是，教授 6 人，副教授 6 人，讲师 5 人，助理实验员 1 人。拥有博士学位者 14 人，拥有硕士学位者 1 人。 教研室教学和科研仪器设备先进，建立了具有开放、创新生物化学与分子生物学 实验室，为开展创新性研究提供了一个十分难得的公共实验平台。
近年来，教研室获得 NSFC-广东联合基金重点项目、国家自然科学基金面上项目 和广东省自然科学基金重点项目等，累计 39 项，在 Nature、Gut、Gastroenterology 、 Nucleic Acids Res、Nature Communications 和 Clin Cancer Res 等杂志发表系列 SCI 研究论文 238 篇论文，累计他引6800 余次，同时拥有中国发明专利 8 项。
肿瘤分子学专业是以汕头大学医学院生物化学与分子生物学教研室为依托，以潮 汕地区高发性肿瘤——食管鳞癌为对象，从生物化学、分子生物学、细胞生物学 及动物个体等多层次水平进行深入研究。主要研究方向，赖氨酰氧化酶家族 （Lysyl Oxidase，LOX family）在食管鳞癌中的功能及其分子作用机制。
The Department of Biochemistry and Molecular Biology of Shantou University Medical College (SUMC) is one of the important basic departments of SUMC, which plays a critical role in Guangdong provincial key disciplines of biochemistry and molecular biology and biology in Shantou University., SUMC was granted the right to confer master's degrees and doctoral degrees in biochemistry and molecular biology in 2000 and 2005 respectively. At present, the Department has a total of 18 faculty members and assistants, including 6 professors, 6 associate professors, 5 assistant professors and 1 assistant experimenter. The staff has 14 with a doctoral degree, 1 with a master's degree, 2 with a bachelor's degree. In addition, there are 6 doctoral supervisors and 6 master supervisors. The Department has advanced equipment for scientific research and has established an open and innovative biochemistry and molecular biology laboratory, which provides a rare public experimental platform for carrying out innovative scientific research.
In recent years, the Department has obtained NSFC-Guangdong Joint Fund Key Projects, National Natural Science Foundation General Projects, and Guangdong Natural Science Foundation Key Projects, etc., a total of 39 projects. It has published 238 research papers in Nature, Gut, Gastroenterology, Nucleic Acids Res, Nature Communications and Clin Cancer Res and other magazines, which have been cited more than 6,800 times, and has 8 Chinese invention patents.
The discipline of Molecular Biology of Cancer is based on the Department of Biochemistry and Molecular Biology of Shantou University Medicine College (SUMC). It targets the high incidence of esophageal squamous cell carcinoma (ESCC) in Coastal Chaoshan Area, Guangdong Province. It conducts in-depth research with multi-level of biochemistry, molecular biology, cell biology and animal models. The main research direction is the function and molecular mechanism of Lysyl Oxidase (LOX family) in esophageal squamous cell carcinoma.
徐建震 Jianzhen Xu
邮箱及联系电话:jzxu01@stu.edu.cn, 86-0754-88900491
Email & Contact Number:jzxu01@stu.edu.cn, 86-0754-88900491
研究方向: 生物信息学
Research Field: Bioinformatics
导师简介 Biography：
汕头大学医学院教授，博士生导师，肿瘤医学信息学学科带头人，生物信息学教 研室主任。全国高等院校计算机基础教育研究会智能技术应用专业委员会常务委 员、中国抗癌协会骨于软组织肿瘤热疗及生物信息学专业委员会常务委员、广东 省生物信息学学会理事。入选广东省“ 扬帆计划 ”高层次人才项目。Frontiers in Genetics 编辑。主要致力于采用系统生物学方法研究 RNA 结合蛋白和非编码 RNA 在细胞信号转导机制中的作用及其与各类疾病的关系。研究成果连续发表 在 Autophagy ，Cell death differ, Comput Struct Biotec, Int J Cancer 等世界知名学 术期刊上。已完成国家自然科学基金项目 2 项和 863 项目子课题 1 项。获得省厅 级自然科学学术一等奖 3 项。申请国内外发明专利和软件著作权等共 3 项。
Professor Xu received his PhD degree from Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, China (2009). He was a visiting professor at Department of Biochemistry and Molecular Biology, University of Georgia, USA (2015-2016). Currently, he leads the Systems Biology Lab at Department of Bioinformatics, Shantou University Medical College. His research has been focused onto topics in cancer genomics or systems biology. He investigates novel non-coding RNAs and RNA binding protein with both computational analysis and molecular and cellular methods in cancers. Professor Xu is a member of Chinese society for cell biology, Chinese society for bioinformatics, American association for cancer research. He has published more than 40 peer-reviewed scientific papers in international journals. Professor Xu's researches are supported by National Natural Science Foundation of China, Top-tier University Development Scheme, Department of Education, Guangdong Government and the Li KaShing Foundation. He is an academic editor for Frontiers in Genetics, Plos One and reviewer for over 30 International peer reviewed journals.
孙源 Yuan Sun
邮箱及联系电话：y.sun.1@outlook.com, 86-13502832838
Email & Contact Number：y.sun.1@outlook.com, 86-13502832838
研究方向: 心血管疾病发生机制及防治药物开发
Research Field：Pathogenesis and therapy of cardiovascular disease
导师简介 Biography：
孙源，2020 年 10 月毕业于荷兰鹿特丹伊拉斯姆斯大学，获药理学博士。2022 年 9 月起，加入汕头大学医学院，任临床医学研究中心特聘教授。主要研究方向 为高血压、糖脂代谢紊乱发生机制及防治药物开发。 曾获美国心脏协会 New Investigator Travel Award 、Paul Dudley White International Scholar、国家自费留学 生奖学金等荣誉。 以第一/共一作者在 Circulation Research 、Hypertension 、 Pharmacological Research、Biomaterials 等专业杂志上发表论文 10 篇。2020 年于 Hypertension 杂志发表的论文曾入选美国心脏协会 2020 年夏季高影响论文，并 受 Hypertension 杂志邀请接受 Twitter chat 线上采访。主持国家自然科学基金项 目 1 项，省市厅级项目 3 项。参与培养博士研究生 4 名，硕士研究生 1 名。
Yuan Sun is a distinguished Professor jointly appointed by Shantou University School of Medicine and the First Affiliated Hospital of Shantou University School of Medicine. Yuan obtained her Ph.D degree in pharmacology from Erasmus University Rotterdam in Oct 2020. Dr. Sun has been focused on understanding the pathogenesis of cardiovascular diseases (CVD) and identifying novel therapeutic targets for CVD. In the past five years, Dr. Sun has published 10 articles in internationally refereed journals, including Circulation Research, Hypertension, Pharmacological Research, and Biomaterials. Her work, entitled “Megalin: a novel endocytic receptor for prorenin and renin” was selected as “High impact paper in Hypertensin for Summer of 2020” by American Heart Association (AHA). She has received several awards, including the AHA New Investigator Travel Award, Paul Dudley White International Scholar and Chinese government award for outstanding self-financed students abroad. She received one National Science Foundation grant and three provincial or municipal grants. She is co-supervising four PhD and one master students.
王茂林 Maolin Wang
邮箱及联系电话：wangml1240@163.com，86-15016058294
Email & Contact Number：wangml1240@163.com，86-15016058294
研究方向: 生物信息学
Research Field：Bioinformatics
导师简介 Biography：
汕头大学医学院和第一附属医院双聘教授。2016 年毕业于北京化工大学，获工 学博士学位，博士期间参与英国剑桥大学联合培养。主要研究方向为肿瘤靶向药 物设计，多组学联合等。主持国家及省市级项目4 项，经费资助金额 200 余万元，
在 Nature Communications、Proceedings of the National Academy of Sciences（PNAS） 等 SCI 期刊上上发表学术论文 10 余篇。另外，参与指导硕士和博士研究生 3 名。
Maolin Wang is a double-appointed professor of Shantou University School of Medicine and the First Affiliated Hospital. He graduated from the Beijing University of Chemical Technology in 2016 with a doctorate degree. During the PhD, he went to University of Cambridge as a joint-supervision student. His research is mainly focusing on design drug targeting various tumors and multiomics research. He has in charge of 4 national, municipal and departmental projects, with a funding amount of more than 2 million yuan, published more than 10 academic papers in SCI journals such as Nature Communications 、Proceedings of the National Academy of Sciences (PNAS). He has participated in the supervision of three master's and doctoral students in the past years.
卢玺峰 Xifeng Lu
邮箱及联系电话： xifeng.lu@outlook.com, 86-13168778436
Email & Contact Number：xifeng.lu@outlook.com, 86-13168778436
研究方向: V-ATPase 与代谢调控
Research Field：The role of Vacuolar H+-ATPase in metabolic regulation
导师简介 Biography：
汕头大学医学院/汕头大学医学院第一附属医院特聘教授。2014 年毕业于荷兰鹿 特丹伊拉斯姆斯，获博士学位。2014 年 11 月至 2021 年 08 月在深圳大学医学部 工作，历任讲师、副教授。2021 年 09 月至 2022 年 08 月在深圳技术大学药学院 工作，任药理学教授。2022 年 09 月起在汕头大学医学院工作。主要研究方向为 胆固醇代谢调控分子机制、V-ATPase 在代谢调控中的作用、以及代谢紊乱性疾
病防治药物的开发。主持国家级项目 3 项，其它省、市、厅级等各类项目 6 项， 总经费金额达 700 余万元人民币。在 Circulation Research、Nature Communications、 Organic Letters、Biomaterials、Pharmacological Research、Frontiers in Cardiovascular Medicine 等一流学术期刊上发表论文 30 余篇，申请并获得国家发明专利授权 1 项。指导硕士研究生 7 名，博士研究生 7 名。
Xifeng Lu is a distinguished Professor jointly appointed by Shantou University School of Medicine and the First Affiliated Hospital of Shantou University School of Medicine. Xifeng Lu was awarded a PhD degree in pharmacology by Erasmus University Rotterdam in Jan 2014. After his PhD, Dr. Lu worked as postdoc fellow at Erasmus Medical Center (EMC, Rotterdam) and Academic Medical Center (AMC, Amsterdam) until he joined Shenzhen University. Dr. Lu served as assistant professor and associate professor at Shenzhen University Health Science Center during Nov 2014 and Aug 2021. From Sep 2021, Dr. Lu served as Professor in Pharmacology at Shenzhen Technology University until he joined Shantou University School of Medicine in Sep 2022. The research of Xifeng focused on elucidating the role of Vacuolar H+-ATPase in metabolic control, identification of novel regulators in cholesterol metabolism, and developing drugs or other therapeutic ways to treat metabolic diseases. Xifeng received 3 grants from NSFC and 6 others grants from Guangdong Province or Shenzhen Municipal, which amounted to more than 7 million RMB. Xifeng has authored more than 30 articles in top-class journals such as Circulation Research, Nature Communications, Organic Letters, Biomaterials, Pharmacological Research, and Frontiers in Cardiovascular Medicine. Till now, Xifeng has supervised/co-supervised 7 master students and 7 PhD students.
沈文君 Wenjun Shen
邮箱及联系电话：wjshen@stu.edu.cn, 86-13676120002
Email & Contact Number：wjshen@stu.edu.cn, 86-13676120002
研究方向: 癌症基因组学、生物信息学、模式识别
Research Field：Cancer genomics，Bioinformatics，Pattern recognition
导师简介 Biography：
沈文君，博士毕业于香港城市大学计算机科学系；斯坦福大学访问学者。现为汕 头大学医学院生物信息教研室，副教授、硕士生导师。主要研究方向包括癌症基 因组学、生物信息学和模式识别，在 Foundations of Computational Mathematics， Journal of Experimental & Clinical Cancer Research, Genome biology, Cell Reports Methods, Cancers, Frontiers in Microbiology, Knowledge-Based Systems, Pattern Recognition 等重要期刊上发表论文 20 余篇。
Dr. Wenjun Shen earned her Ph.D. in Computer Science from the City University of Hong Kong. From 2019 to 2020, she served as a visiting scholar at the School of Medicine, Stanford University. Currently, she is an associate professor in the
Department of Bioinformatics at Shantou University Medical College. Her research focuses on cancer genomics, bioinformatics, and pattern recognition. She has authored over 20 papers in prestigious journals, including Foundations of Computational Mathematics, Journal of Experimental & Clinical Cancer Research, Genome Biology, Cell Reports Methods, Cancers, Frontiers in Microbiology, Knowledge-Based Systems, and Pattern Recognition.